Assess the efficacy of lapatinib in patients with metastatic HER2‐negative BC but HER2‐positive CTCs (≥2 CTCs/7.5mL as assessed by the CellSearch® system, with a HER2 status evaluated by immunofluorescence and FISH) who had received at least one line of therapy. Here, ERBB2 is linked to breast cancer.